Because of the high mutation rate in melanoma cells, cancer drugs have been developed to help target these signaling pathways that stimulate such rapid growth. While many of these drugs have proven to be successful, resistance to these same drugs can also occur.
When it comes to cutaneous malignant melanoma (CMM), BRAFV600E is a common mutation found in approximately 50% of cases. Currently, BRAF mutations are detected by using DNA tests, but there may be an alternative assay that's less expensive, requires less tissue, more efficient, and thought to be more sensitive.
Of the 39 advanced gastric cancer patients treated with the immunotherapy antibody, pembrolizumab (Keytruda, Merck), 22.2% had an objective response. The median time to response was 8 weeks and the median progression-free survival (PFS) was 1.9 months
No difference in anxiety was found among patients with non-Hodgkin lymphoma who were assigned to maintenance rituximab compared with those patients who were assigned to rituximab re-treatment upon disease progression, results of a recent study show.